US Representative

Gary Palmer Authored & Sponsored Legislation

Session

Primary Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2076

Introduced
3/11/25  
Lulu’s Law

Co-Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB21

Introduced
1/3/25  
Refer
1/3/25  
Born-Alive Abortion Survivors Protection Act This bill establishes requirements for the degree of care a health care practitioner must provide in the case of a child born alive following an abortion or attempted abortion. Specifically, a health care practitioner who is present must (1) exercise the same degree of care as would reasonably be provided to any other child born alive at the same gestational age, and (2) ensure the child is immediately admitted to a hospital. Additionally, a health care practitioner or other employee who has knowledge of a failure to comply with the degree-of-care requirements must immediately report such failure to law enforcement. A health care practitioner who fails to provide the required degree of care, or a health care practitioner or other employee who fails to report such failure, is subject to criminal penalties—a fine, up to five years in prison, or both. An individual who intentionally kills or attempts to kill a child born alive is subject to prosecution for murder. The bill bars the criminal prosecution of a mother of a child born alive under this bill and allows her to bring a civil action against a health care practitioner or other employee for violations.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2126

Introduced
3/14/25  
FOCA Act of 2025 Fair and Open Competition Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB22

Introduced
1/3/25  
Refer
1/3/25  
SAVE Act Safeguard American Voter Eligibility Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2205

Introduced
3/18/25  
NEDD Act Nuclear Ecosystem Drone Defense Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2222

Introduced
3/18/25  
Lowering Egg Prices Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2288

Introduced
3/24/25  
Common Sense Air Regulations Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB24

Introduced
1/3/25  
Federal Reserve Transparency Act of 2025This bill directs the Government Accountability Office (GAO) to complete, within 12 months, an audit of the Federal Reserve Board and Federal Reserve banks. In addition, the bill allows the GAO to audit the Federal Reserve Board and Federal Reserve banks with respect to (1) international financial transactions; (2) deliberations, decisions, or actions on monetary policy matters; (3) transactions made under the direction of the Federal Open Market Committee; and (4) discussions or communications among Federal Reserve officers, board members, and employees regarding any of these matters.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2581

Introduced
4/1/25  
Iranian Terror Prevention Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB27

Introduced
1/3/25  
Refer
1/3/25  
Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl ActThis bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).Additionally, the bill establishes a new, alternative registration process for certain schedule I research.The bill also makes several other changes to registration requirements for conducting research with controlled substances, includingpermitting a single registration for related research sites in certain circumstances,waiving the requirement for a new inspection in certain situations, andallowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.Finally, the bill expresses the sense that Congress agrees with the interpretation of Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.